Proxofim Peptide (FOXO4-DRI): Cellular Aging and Senescence Research

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Proxofim, known in research literature as FOXO4-DRI (FOXO4-D-Retro-Inverso), represents a senolytic peptide designed to selectively induce apoptosis in senescent cells. First introduced in a 2017 Cell publication, this modified peptide has opened new avenues for studying cellular senescence and tissue homeostasis in laboratory models.^[1]

The compound targets the FOXO4-p53 protein interaction that maintains senescent cell viability. By disrupting this interaction, researchers can study how senescent cell clearance affects aging processes, tissue function, and disease progression in controlled experimental settings.

Key Highlights

• Tesamorelin features N-terminal hexenoyl modification that increases enzymatic stability compared to native GHRH
• Activates GHRH receptors through Gsα-cAMP-PKA signaling pathway to trigger pulsatile growth hormone secretion
• Upregulates oxidative phosphorylation genes while downregulating inflammatory and fibrogenic pathways in hepatic tissue
• Provides research tool for investigating GH/IGF-1 axis biology, mitochondrial function, and metabolic regulation

What is Proxofim Peptide (FOXO4-DRI)?

Proxofim is a modified peptide constructed using D-amino acids in a retro-inverso configuration. This design increases resistance to proteolytic degradation while maintaining the biological activity needed to disrupt specific protein-protein interactions.

The peptide sequence derives from the forkhead domain of FOXO4, a transcription factor that plays a role in cellular stress responses. Researchers synthesize this peptide to interfere with FOXO4’s ability to bind and sequester p53 within senescent cells.

According to structural studies published in Nature Communications, the peptide binds to the disordered p53 transactivation domain and forms a transiently folded complex. This binding competitively inhibits native FOXO4 from maintaining its anti-apoptotic interaction with p53.^[2]

The cell-penetrating properties of the peptide allow it to cross cellular membranes in experimental systems. Once inside cells, it can access the nuclear compartment where FOXO4-p53 interactions occur.

Related Product: Buy FOXO4-DRI for laboratory research use.

The Role of Senescence in Cellular Aging

Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, telomere attrition, oncogenic stress, or oxidative damage. Senescent cells accumulate in tissues during natural aging and after injury or disease.^[3]

These cells resist apoptosis through multiple survival pathways. They also secrete inflammatory cytokines, growth factors, and proteases collectively known as the senescence-associated secretory phenotype (SASP).

The SASP can affect neighboring cells and alter tissue microenvironments. In acute settings, senescent cells contribute to wound healing and tissue remodeling, but their persistent accumulation has been linked to age-related tissue dysfunction in laboratory models.

Research using genetic clearance methods in mice demonstrates that eliminating senescent cells can delay certain age-associated phenotypes. These findings have driven interest in senolytic compounds as research tools for studying the mechanisms connecting cellular senescence to organismal aging.^[4]

FOXO4-p53: The Senescent Cell Survival Mechanism

The transcription factor p53 typically induces apoptosis when cells accumulate DNA damage. In senescent cells, FOXO4 binds to p53 and sequesters it in nuclear bodies, preventing p53 from triggering cell death pathways.

This interaction creates an apoptosis-resistant state that allows senescent cells to persist in tissues. The FOXO4-p53 complex formation depends on specific binding domains in both proteins.

Research shows that p53 phosphorylation enhances the affinity for both FOXO4 and FOXO4-DRI. Senescent cells often display elevated levels of phosphorylated p53, particularly at serine 15, which strengthens the FOXO4-p53 interaction.^[2]

NMR structural analysis reveals that both FOXO4 and FOXO4-DRI bind to intrinsically disordered regions of p53. The competitive binding mechanism allows the exogenous peptide to displace endogenous FOXO4 from the complex.

When FOXO4-DRI disrupts this interaction, p53 relocates from the nucleus to the cytoplasm. This nuclear exclusion restores p53’s pro-apoptotic function specifically in senescent cells that depend on FOXO4 for survival.

How Proxofim (FOXO4-DRI) Works

The D-retro-inverso modification reverses the peptide sequence and replaces L-amino acids with D-amino acids. This creates a molecule with similar binding properties but increased stability against enzymatic degradation.

The peptide contains both the FOXO4-derived binding region and a cationic cell-permeability sequence. Both components contribute to the interaction with p53 and cellular uptake in experimental systems.

In senescent cell cultures, Proxofim treatment promotes p53 nuclear exclusion within hours. The cytoplasmic p53 then activates apoptotic pathways, leading to selective death of senescent cells.

Non-senescent cells show minimal response to the peptide. This selectivity appears to depend on the elevated FOXO4 expression and p53 phosphorylation state characteristic of senescent cells.

Third-Party Tested, USA-Made, 99% Purity

Lyophilized peptides for laboratory applications. 99% purity, 100% USA-Made.

Research Applications and Study Findings

Proxofim has been applied across multiple research areas to investigate senescent cell biology and tissue aging mechanisms. The following sections detail key experimental findings from peer-reviewed studies.

Tissue Homeostasis and Aging Models

The original 2017 research demonstrated that Proxofim could neutralize doxorubicin-induced cellular damage in mouse models. Animals treated with the chemotherapy drug typically develop senescent cell accumulation and associated tissue dysfunction.^[1]

In naturally aged mice, peptide administration restored several age-related phenotypes. Researchers observed improvements in fur density, physical fitness markers, and renal function parameters in both fast-aging and naturally aged animal models.

The study showed that senescent cell clearance could restore tissue homeostasis even after age-related decline had occurred. This temporal flexibility makes the peptide useful for studying both preventive and restorative mechanisms in aging research.

Fibrotic Disease Models

Research on pulmonary fibrosis found that Proxofim decreased senescent cell populations and downregulated SASP gene expression in bleomycin-induced lung injury models. The peptide treatment reduced collagen deposition and morphological changes associated with fibrosis.^[5]

The study identified myofibroblasts as a preferential target for the peptide. These contractile cells drive fibrotic scarring, and their elimination led to downregulation of extracellular matrix receptor interaction pathways.

Type 2 alveolar epithelial cells increased in number following treatment, while myofibroblast populations decreased. This shift in cellular composition correlated with improved lung architecture in the experimental models.

Keloid research revealed elevated p16 expression and increased senescent fibroblast populations in pathological scar tissue. Proxofim treatment induced apoptosis in these senescent fibroblasts by promoting nuclear exclusion of phosphorylated p53-serine15.^[6]

The peptide decreased G0/G1 phase cells and altered the cell cycle distribution in keloid organ cultures and isolated fibroblasts. These findings suggest potential research applications in studying fibroblast senescence and scar formation mechanisms.

Endocrine and Metabolic Research

Studies on testicular aging showed that FOXO4 translocates to the nucleus in aged Leydig cells, where it correlates with decreased testosterone synthesis. Hydrogen peroxide-induced senescent Leydig cells maintained viability through FOXO4-dependent mechanisms.^[7]

Proxofim treatment selectively induced apoptosis in these senescent Leydig cells by disrupting the FOXO4-p53 interaction. In aged mice, this intervention improved the testicular microenvironment and age-related hormonal parameters.

The research demonstrates how senescent cell accumulation in endocrine tissues can be studied using senolytic peptides. This model system allows investigation of how cellular senescence affects hormone-producing cell populations.

Neonatal Lung Development Studies

Research on bronchopulmonary dysplasia in neonatal rats exposed to hyperoxia identified cellular senescence as a contributor to disease progression. The study found increased oxidative DNA damage, tumor suppressor expression, and SASP markers in affected lung tissue.^[8]

Proxofim administration decreased cellular senescence markers and improved alveolar complexity in the experimental models. The treatment partially maintained type 2 alveolar cell populations compared to untreated controls.

Single-cell RNA sequencing revealed increased senescence signatures across multiple cell types in the hyperoxia-exposed lungs. The peptide’s effects on these diverse populations highlight the broad research applications for studying senescence in developmental and injury contexts.

Potential In Vitro Research Applications

Research Area	Laboratory Applications
Senescence Biology	Mechanistic studies of FOXO4-p53 interactions, apoptosis pathway investigation, SASP characterization
Fibrosis Models	Myofibroblast senescence, extracellular matrix regulation, tissue remodeling pathways
Aging Research	Cellular aging phenotypes, tissue homeostasis mechanisms, age-related protein modifications
Endocrine Function	Hormone-producing cell senescence, testicular aging models, Leydig cell biology
Developmental Biology	Hyperoxia-induced senescence, alveolar cell differentiation, lung maturation studies
Cancer Biology	Therapy-induced senescence, senescent tumor cell elimination, p53 pathway modulation

Research-Grade Proxofim from BioLongevity Labs

BioLongevity Labs supplies research-grade Proxofim peptide in USA GMP facilities with triple third-party testing verification. Each batch undergoes HPLC purity analysis, LC-MS molecular confirmation, and sterility testing to ensure 99%+ purity for laboratory applications.

Comprehensive Certificates of Analysis (COAs) from independent certified laboratories are available for verification before purchase. This documentation provides researchers with the analytical confidence needed for reproducible experimental work.

This product is strictly for research use only and not for human consumption or any therapeutic application.

Quick Review

Proxofim (FOXO4-DRI) provides researchers with a molecular tool for investigating senescent cell biology and the role of cellular senescence in tissue aging. The peptide’s selective mechanism targeting the FOXO4-p53 interaction has enabled diverse research applications across fibrotic diseases, endocrine function, developmental biology, and aging studies.

As the field of senescence research continues to expand, senolytic peptides like Proxofim will remain valuable for dissecting the complex relationships between cellular senescence, tissue homeostasis, and age-related physiological changes in laboratory models.

References

1. Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Elsevier BV; 2017. https://doi.org/10.1016/j.cell.2017.02.031
2. Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, Zhou Q, Usluer S, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Springer Science and Business Media LLC; 2025. https://doi.org/10.1038/s41467-025-60844-9
3. McHugh D, Gil J. Senescence and aging: causes, consequences, and therapeutic avenues. Rockefeller University Press; 2017. https://doi.org/10.1083/jcb.201708092
4. Yousefzadeh MJ, Melos KI, Angelini L, Burd CE, Robbins PD, Niedernhofer LJ. Mouse models of accelerated cellular senescence. Springer New York; 2018. https://doi.org/10.1007/978-1-4939-8931-7_17
5. Han X, Yuan T, Zhang J, Shi Y, Li D, Dong Y, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM–receptor interaction pathway. Wiley; 2022. https://doi.org/10.1111/jcmm.17333
6. Kong YX, Li ZS, Liu YB, Pan B, Fu X, Xiao R, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Springer Science and Business Media LLC; 2025. https://doi.org/10.1038/s42003-025-07738-0
7. Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Impact Journals, LLC; 2020. https://doi.org/10.18632/aging.102682
8. Jing X, Jia S, Teng M, Day BW, Afolayan AJ, Jarzembowski JA, et al. Cellular senescence contributes to the progression of hyperoxic bronchopulmonary dysplasia. Oxford University Press (OUP); 2024. https://doi.org/10.1165/rcmb.2023-0038oc